Article citationsMore>>

Ajani, J.A., Estrella, J.S., Chen, Q., Correa, A.M., Ma, L., Scott, A.W., et al. (2018) Galectin-3 Expression Is Prognostic in Diffuse Type Gastric Adenocarcinoma, Confers Aggressive Phenotype, and Can Be Targeted by YAP1/BET Inhibitors. British Journal of Cancer, 118, 52-61.
https://doi.org/10.1038/bjc.2017.388

has been cited by the following article:

• TITLE: The Regulatory Mechanism and Therapeutic Targets of the HIPPO Pathway in Helicobacter pylori-Associated Gastric Cancer

  AUTHORS: Hao Tan, Ping Lu

  KEYWORDS: Helicobacter pylori, Gastric Cancer, HIPPO Pathway, YAP/TAZ, CagA

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.9, September 3, 2025

  ABSTRACT: The HIPPO signaling pathway critically regulates cell proliferation, apoptosis, and tissue homeostasis, playing a pivotal role in Helicobacter pylori (H. pylori)-associated gastric cancer, a major contributor to the global gastric cancer burden. Dysregulation of HIPPO signaling, particularly through YAP/TAZ activation, drives tumorigenesis, invasion, and metastasis in H. pylori-infected gastric tissues. This review elucidates the molecular mechanisms by which H. pylori virulence factors, such as CagA, disrupt HIPPO pathway components, including MST1/2 and LATS1/2 kinases, and explores epigenetic and pathway crosstalk mechanisms. We also discuss promising therapeutic targets, including YAP/TAZ inhibitors and combination strategies with H. pylori eradication therapies. These insights aim to guide the development of targeted interventions for H. pylori-related gastric malignancies.